 NEW YORK, March 25, 2021 PRNewswire -- Actinium Pharmaceuticals, Inc. NYSE AMERICAN: ATNM Actinium or the Company today announced that initial patient enrollment in the second dose cohort in the Phase 1 portion of the Actimab-A venetoclax Phase 12 combination trial in fit and unfit patients with relapsed or refractory Acute Myeloid Leukemia rr AML has been completed. The Phase 1 portion of the trial is a 3 3 dose escalation study to determine the maximum tolerable dose of Actimab-A that is to be studied in the Phase 2 portion of the study. 